BRITAIN-HEALTH-VIRUS-SCIENCE-DRUGS
Protein scientist Simon Varzandeh conducts an enzyme assay as he works in the laboratory of British pharmatech company Exscientia at Oxford Science Park in Oxford, in southern central England, on April 24, 2020 as part of the company's joint initiative to test existing clinical molecules to find a treatment for the COVID-19 illness. - British pharmatech company Exscientia has teamed up with Diamond Light Source, the UK's national synchrotron facility, and Calibr, a division of US institute Scripps Research to screen Calibr's collection of 15,000 clinically-ready molecules in an effort to identify drugs with the potential to treat COVID-19. (Photo by Adrian DENNIS / AFP) (Photo by ADRIAN DENNIS/AFP via Getty Images)
PURCHASE A LICENCE
How can I use this image?
£375.00
GBP
DETAILS
Restrictions:
Contact your local office for all commercial or promotional uses. Full editorial rights UK, US, Ireland, Italy, Spain, Canada (not Quebec). Restricted editorial rights elsewhere, please call local office.
Credit:
Editorial #:
1210875333
Collection:
AFP
Date created:
24 April, 2020
Upload date:
Licence type:
Release info:
Not released. More information
Source:
AFP
Barcode:
AFP
Object name:
AFP_1QS9H5
Max file size:
5472 x 3648 px (46.33 x 30.89 cm) - 300 dpi - 3 MB
- Laboratory,
- UK,
- Enzyme,
- Assay - Scientific Procedure,
- Business,
- Business Finance and Industry,
- COVID-19,
- Chemistry,
- Discovery,
- Drug,
- Effort,
- England,
- Epidemic,
- Healthcare And Medicine,
- Identity,
- Illness,
- Infectious Disease,
- Initiative,
- Molecule,
- Opportunity,
- Oxford - England,
- Pandemic - Illness,
- Protein,
- Science and Technology,
- Scientist,
- Scrutiny,
- Working,